{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-22-003323","form_type":"8-K","ticker":"CLDX","cik":"0000744218","company_name":"Celldex Therapeutics, Inc.","filed_at":"2022-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:04:03.553885+00:00","generated_at":"2026-06-26T00:07:47.799866+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Celldex Q1 net loss $0.49/share; cash $380.5M; barzolvolimab Ph2 starts Q2 2022","bullets":["Net loss of $23.1M ($0.49 per share) vs $16.5M ($0.42) a year ago; revenue fell to $0.2M from $0.7M.","Cash, cash equivalents and marketable securities $380.5M at March 31, 2022; sufficient to fund operations through 2025.","R&D expenses increased to $17.1M from $12.7M; G&A expenses $6.9M vs $4.1M, driven by clinical and commercial planning.","Phase 2 studies of barzolvolimab in chronic spontaneous and inducible urticaria to initiate Q2 2022; Phase 1b CSU data submitted to EAACI.","Barzolvolimab expansion into eosinophilic esophagitis with Phase 2 planned Q4 2022; enrollment continues in prurigo nodularis and inducible urticaria."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-22-003323","json":"https://secwatch.observer/filing/0001171843-22-003323.json","markdown":"https://secwatch.observer/filing/0001171843-22-003323.md","text":"https://secwatch.observer/filing/0001171843-22-003323.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/744218/000117184322003323/0001171843-22-003323-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/744218/000117184322003323/f8k_050522.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T00:07:47.799866+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}